Syndax Pharmaceuticals Return on Equity

Syndax Pharmaceuticals (SNDX) currently reports a ROE of 1219.34%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Syndax Pharmaceuticals's ROE history and peer comparisons.

Syndax Pharmaceuticals's ROE of 1219.34% is higher than the Healthcare sector average of -75.84%. That is roughly 1707.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Syndax Pharmaceuticals's current 1219.34% should be judged against Healthcare norms (sector average: -75.84%) and against SNDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1219.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Syndax Pharmaceuticals, and consider following SNDX for alerts when major investors trade the stock.

Syndax Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 1219.34% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNDX with unrelated industries.